Stock listing

BX Swiss:DYN Dyne Therapeutics, Inc. Aktie

Swiss listing (BX Swiss) of Dyne Therapeutics, Inc. · home listing NASDAQ:DYN

Follow Dyne Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:DYN

$15.50 USD -0.37 (-2.3%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:DYN

Past year -23.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$15.41 – $16.48 USDNov 20, 2026
Volume
2.23M sharesNov 20, 2026
Market cap
$2.90B USDAt the close on Nov 20, 2026 · price × 187.4M shares outstanding
52-week range
$14.00 – $27.31 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$51.99M USDMedian day 2.53M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Dyne Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:DYN · Home$15.50 USD-0.37 (-2.3%)2,231,136$15.91$16.48$15.41$15.87Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DYN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$15.50-0.37-2.3%$15.91$16.48$15.412,231,136
$15.87-0.15-0.9%$15.92$16.56$15.872,927,669
$16.02-0.68-4.1%$16.70$16.85$15.922,058,012
$16.70-0.46-2.7%$16.92$17.24$16.491,849,636
$17.16+0.15+0.9%$16.90$17.35$16.421,674,293
$17.01-0.98-5.4%$17.70$17.78$17.012,311,962
$17.99+0.07+0.4%$18.10$18.31$17.851,909,757
$17.92-0.70-3.8%$18.29$18.64$17.332,392,553
$18.62+0.55+3.0%$18.51$19.00$17.893,860,440
$18.07+0.71+4.1%$17.68$18.33$17.402,359,185
$17.36-1.18-6.4%$18.78$18.78$17.333,203,978
$18.54+0.49+2.7%$18.57$19.00$17.943,649,277
$18.05+0.75+4.3%$17.53$18.15$17.322,815,818
$17.30+0.61+3.7%$16.81$17.35$16.712,907,337
$16.69-0.35-2.1%$17.04$17.19$16.341,449,801
$17.04+0.06+0.4%$17.20$17.59$16.751,427,300
$16.98+0.04+0.2%$16.30$17.12$16.112,177,500
$16.94+1.22+7.8%$15.80$16.97$15.733,002,000
$15.72+0.10+0.6%$15.64$16.02$15.531,741,900
$15.62-0.15-1.0%$15.92$15.92$15.322,134,300
$15.77-0.30-1.9%$15.99$16.34$15.672,052,500
$16.07-0.20-1.2%$16.33$16.73$15.911,789,800
$16.27+1.04+6.8%$15.27$16.56$15.143,405,300
$15.23+0.98+6.9%$14.45$15.38$14.453,346,200
$14.25-1.04-6.8%$15.21$15.49$14.132,860,500
$15.29+0.25+1.7%$15.15$15.47$15.042,074,600
$15.04-0.26-1.7%$15.11$15.42$14.712,195,900
$15.30-0.66-4.1%$15.97$15.99$15.283,341,600
$15.96-0.68-4.1%$16.54$16.76$15.732,915,100
$16.64+0.27+1.6%$16.41$17.31$16.363,565,900
$16.37+0.40+2.5%$15.84$16.47$15.356,279,500
$15.97+0.57+3.7%$15.40$16.12$15.253,489,900
$15.40-0.04-0.3%$15.50$15.59$14.934,098,700
$15.44+0.24+1.6%$15.31$15.54$15.084,377,300
$15.20-0.62-3.9%$16.03$16.03$15.092,534,100
$15.82-0.29-1.8%$16.01$16.28$15.523,699,400
$16.11-0.10-0.6%$16.05$16.80$15.924,456,500
$16.21-0.13-0.8%$16.40$16.55$15.972,287,000
$16.34+0.31+1.9%$15.86$16.43$15.632,305,800
$16.03-0.48-2.9%$16.62$16.76$16.021,612,100
$16.51+0.28+1.7%$16.09$16.65$15.883,197,700
$16.23-0.91-5.3%$17.08$17.08$16.182,636,200
$17.14+0.02+0.1%$17.39$17.59$17.062,627,000
$17.12+0.01+0.1%$17.31$17.59$16.753,219,800
$17.11-0.95-5.3%$18.07$18.15$16.964,849,100
$18.06+0.755+4.4%$17.90$18.11$17.622,846,800
$17.31-0.595-3.3%$18.37$18.37$17.092,156,000
$17.90-0.62-3.3%$18.52$18.62$17.873,029,200
$18.52+0.31+1.7%$18.40$19.15$18.273,196,900
$18.21-0.21-1.1%$18.59$18.74$17.943,774,300
$18.42-0.77-4.0%$19.03$19.03$17.934,709,500
$19.19-1.12-5.5%$19.38$20.16$18.975,143,000
$20.31-3.97-16.4%$17.08$20.91$17.0017,173,100
$24.28-0.67-2.7%$24.59$24.70$24.141,588,000
$24.95-0.19-0.8%$25.26$25.39$24.601,453,500
$25.14+0.04+0.2%$25.55$26.18$24.922,180,600
$25.10-0.33-1.3%$24.99$25.40$24.721,629,400
$25.43+0.36+1.4%$24.92$25.65$24.582,769,300
$25.07-1.02-3.9%$25.82$25.98$24.831,186,900
$26.09-0.27-1.0%$26.29$26.49$25.981,018,700
$26.36+0.02+0.1%$26.32$26.47$25.781,527,800
$26.34+0.35+1.3%$26.28$26.69$25.971,459,196
$25.99-0.11-0.4%$26.13$26.14$25.141,370,092
$26.10+0.12+0.5%$26.22$26.87$26.021,181,800
$25.98-0.80-3.0%$26.33$26.43$25.681,484,300
Ticker
BX Swiss:DYN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BX Swiss
Currency
CHF

What changed lately

Latest news

All Dyne Therapeutics, Inc. news

Dyne Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
34 in the last 12 months · 146 in all · newest Nov 19, 2026 · oldest 2020
Decks
15 decks · latest Sep 29, 2026

Where Dyne Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:DYN · Home listingNASDAQUnited StatesUSD
BOATS:DYNBOATSUnited StatesUSD
BX Swiss:DYN · This pageBX SwissSwitzerlandCHF

Valuation

Price/book 3.1× against a median of 3.9×: 3rd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.97B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
3.1×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.2×
Beta vs S&P 500
1.51

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Dyne Therapeutics, Inc. · NASDAQ:DYNUS$2.90BUS$1.97Bn/an/an/a3.1×n/a0.2×1.51
Iovance Biotherapeutics, Inc. · NASDAQ:IOVAUS$3.19BUS$2.86Bn/a7.5×n/a3.9×−58.2%0.1×1.62
AbCellera Biologics Inc. · NASDAQ:ABCLUS$3.16BUS$2.53Bn/a37.3×n/a3.0×−218.5%0.1×2.42
Viking Therapeutics, Inc. · NASDAQ:VKTXUS$3.16BUS$2.20Bn/an/an/a5.4×n/a0.0×1.31
Lin BioScience, Inc. · TPEX:6696US$3.01BUS$2.50Bn/an/an/a9.3×n/a0.0×n/a
Legend Biotech Corp. · NASDAQ:LEGNUS$2.97BUS$2.28Bn/a1.7×27.0×2.3×−0.0%0.1×0.75
Denali Therapeutics Inc. · NASDAQ:DNLIUS$2.96BUS$2.69Bn/a126×n/a3.2×n/a0.3×1.30
Shanghai Junshi Biosciences Co., Ltd. Class A · SSE:688180US$2.89BUS$3.00Bn/a8.0×n/a3.2×−35.0%0.7×n/a
SELLAS Life Sciences Group, Inc. · NASDAQ:SLSUS$2.78BUS$2.65Bn/an/an/a21.1×n/a0.0×2.19
HLB Co., Ltd. · KRX:028300US$2.67BUS$2.67Bn/a36.9×n/a10.4×−219.1%0.2×n/a
Celcuity Inc. · NASDAQ:CELCUS$2.62BUS$1.98Bn/an/an/an/an/an/a1.10
Median of the othersUS$2.96BUS$2.59B22.4×27.0×3.9×−58.2%0.1×1.31

Forecasts

12 strong buy · 3 buy · 1 hold · 1 sell · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
34.33 USD · Analysts' mean
EPS, year to Dec 2026
-3.89 · 10 analysts

Team and board

Officers

OfficerRole
John CoxPresident and Chief Executive Officer
Erick J. LuceraChief Financial Officer
Alessandro MartuscelliChief Legal Officer
Axel WiestSenior Vice President, Head of Portfolio Strategy & Operations
Debra FeldmanChief Regulatory Affairs Officer
Doug KerrHead of Research & Development and Chief Medical Officer
James P. BilottaChief Digital Information Officer
Johanna Friedl-NadererChief Commercial Officer
José JuvesChief Corporate & Patient Affairs Officer
Lucia CelonaChief Human Resources Officer
Monica FayChief Medical Affairs Officer
Oxana BeskrovnayaChief Innovation Officer
Raj ManchandaChief Technical Officer
Ranjan BatraChief Scientific Officer
Vikram RanadeChief Business Officer

Board

DirectorRole
Jason RhodesChairman
Alessandro MartuscelliChief Legal Officer
Axel WiestSenior Vice President, Head of Portfolio Strategy & Operations
Barry GreeneBoard Member
Brian PosnerBoard Member
Carlo IncertiBoard Member
Catherine Stehman-BreenBoard Member
David LubnerBoard Member
Debra FeldmanChief Regulatory Affairs Officer
Dirk KerstenBoard Member
Ed HurwitzBoard Member
Erick J. LuceraChief Financial Officer
James P. BilottaChief Digital Information Officer
Johanna Friedl-NadererChief Commercial Officer
John CoxPresident and Chief Executive Officer
José JuvesChief Corporate & Patient Affairs Officer
Lucia CelonaChief Human Resources Officer
Monica FayChief Medical Affairs Officer
Oxana BeskrovnayaChief Innovation Officer
Raj ManchandaChief Technical Officer
Ranjan BatraChief Scientific Officer
Vikram KarnaniBoard Member
Vikram RanadeChief Business Officer

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−6.4%
Q2 2026Jul 29, 2026 · After close+2.5%
Q1 2026May 11, 2026 · Before open+4.8%
Q4 2025Feb 26, 2026−2.9%
Q3 2025Nov 5, 2025 · After close−12.9%
Q2 2025Jul 28, 2025 · After close−1.2%
Q1 2025May 8, 2025 · Before open+20.2%
Q4 2024Mar 3, 2025 · Before open−9.5%
Q3 2024Nov 12, 2024 · Before open+4.3%
Q2 2024Aug 12, 2024 · After close+1.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024 · After close+0.3%
Q4 2023Mar 5, 2024 · Before open−6.6%
Q3 2023Oct 30, 2023 · Before open+10.6%
Q2 2023Aug 3, 2023 · Before open−2.2%
Q1 2023May 11, 2023 · Before open−2.8%
Q4 2022Mar 2, 2023 · Before open+5.1%
Q3 2022Nov 3, 2022 · Before open+9.6%
Q2 2022Aug 4, 2022 · Before open+3.1%
Q1 2022May 2, 2022 · After close+3.5%
Q4 2021Mar 10, 2022 · Before open+1.2%

Open Events

Decks

DeckKindSlidesDate
World Muscle Society 31st Annual Congress 2026Conference22 slidesSep 29, 2026
RNA Leaders US 2026Conference19 slidesSep 25, 2026
44th Annual J.P. Morgan Healthcare Conference 2026Conference31 slidesJan 12, 2026
Technical Presentation (2026)Technical17 slides2026
Corporate Update (December 2025)Corporate update34 slidesDec 8, 2025
Corporate Update (June 2025)Corporate update29 slidesJun 17, 2025
Corporate Update (January 2025)Corporate update43 slidesJan 10, 2025
Technical Presentation (September 2024)Technical26 slidesSep 3, 2024
Corporate Update (May 2024)Corporate update47 slidesMay 20, 2024
2024 AAN Annual MeetingConference11 slidesApr 15, 2024
All 15 decks
DeckKindSlidesDate
AAN Annual Meeting 2023Conference8 slidesApr 25, 2023
American Society of Gene & Cell Therapy 2022Conference15 slidesMay 16, 2022
Muscle Study Group Annual Scientific Meeting 2021Conference29 slidesNov 4, 2021
FSHD IRC 2021Conference11 slidesJun 25, 2021
ASGCT Annual Meeting 2021Conference19 slidesMay 14, 2021

Open Decks

Financings

RaiseDate
Public offering of common stock
Made bigger: US$375.15M · US$20.5 a share · Morgan Stanley +5
Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Evercore ISI (co-lead), LifeSci Capital (co-lead), Raymond James (co-lead), Jones
Jul 22, 2026
Public offering of common stock
Closed: US$402.5M raised · US$18.44 a share · Morgan Stanley +3
Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead)
Dec 11, 2025
Public offering of common stock
Closed: US$230M raised · US$8.25 a share · Morgan Stanley +4
Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead), Jones
Jul 2, 2025
At-the-market programme of common stock
Closed: US$140.6M raised
Use of proceeds: To fund operations, together with existing cash, at least into the second half of 2026
Feb 27, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$19.00 a share on Sep 16, 2020.

Price
US$19.00 a share
Shares offered
12,251,578 shares of common stock
Offering size
US$232.8 million
Underwriters' option
Up to 1,837,736 more shares
Underwriters
J.P. Morgan, Jefferies, Piper Sandler, Stifel · In the order on the cover
Shares delivered
On or about Sep 21, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceJul 23, 2020
Filed publiclyAug 25, 2020
Amended onceSep 10, 2020
Shares registered with an exchangeSep 11, 2020
Declared effective by the SECSep 16, 2020
Final prospectus, with the priceSep 17, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Sep 17, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue00000000506.0M1.37B
Cost of revenue2.05M2.24M2.46M3.35M1.09M700.0K271.0K24.0K2.93B2.28B
Gross profit-2.05M-2.24M-2.46M-3.35M-1.09M-700.0K-271.0K-24.0K-2.43B-915.0M
Research and development398.3M281.4M210.8M142.8M121.3M45.2M11.0M4.28M
Selling, general and administrative69.9M62.5M31.4M28.2M28.7M13.4M2.79M517.0K189.0M161.0M
Operating income-468.2M-343.9M-242.2M-171.0M-150.0M-58.6M-13.8M-4.79M-412.0M-640.0M
Depreciation and amortization2.05M1.67M1.67M1.68M1.09M700.0K271.0K24.0K867.0M766.0M
EBITDA-466.1M-342.2M-240.5M-169.3M-148.9M-57.9M-13.6M-4.77M455.0M126.0M
Interest expense6.19M002.92M742.0K396.0K290.0K5.00K616.0M625.0M
Income before tax-446.2M-317.4M-235.9M-168.1M-149.3M-59.4M-14.9M-4.81M-538.0M-1.29B
Income tax000-2.86M-8.00K-700.0K-1.32M-11.0K-610.0M-45.0M
Net income-446.2M-317.4M-235.9M-168.1M-149.3M-59.4M-14.9M-4.81M76.0M-1.24B
Earnings per share, basic-3.47-3.37-3.95-3.23-2.93-4.13-6.08-0.470.47-9.61
Earnings per share, diluted-3.47-3.37-3.95-3.23-2.93-4.13-6.08

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents893.4M435.4M121.6M172.1M200.8M300.9M14.6M8.12M365.0M1.78B
Short-term investments217.2M206.8M1.47M83.9M175.7M44.5M032.0M130.0M
Receivables513.0M386.0M
Inventory445.0M445.0M
Current assets1.13B659.3M129.4M265.6M382.4M349.1M14.8M8.16M1.52B2.99B
Property, plant and equipment24.0M5.40M4.78M5.95M4.68M1.95M1.49M110.0K
Goodwill772.0M799.0M
Total assets1.19B691.2M165.1M306.3M425.7M353.3M16.4M8.27M11.8B13.1B
Accounts payable8.08M6.56M22.9M5.26M4.03M3.44M1.26M518.0K367.0M332.0M
Current liabilities50.6M42.3M51.1M28.1M28.7M11.0M2.36M711.0K1.05B916.0M
Long-term debt148.9M
Total debt148.9M027.4M30.5M32.6M3.38M8.43B8.98B
Total liabilities214.8M61.4M73.8M54.0M57.5M11.0M2.40M13.1M9.87B11.0B
Shareholders' equity972.1M629.8M91.3M252.4M368.2M342.4M14.0M-4.88M1.90B2.04B
Shares outstanding165.0M102.3M61.5M55.6M51.6M45.1M2.59M10.3M162.0M129.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-403.2M-292.4M-188.2M-153.6M-119.6M-46.5M-11.8M-4.16M585.0M676.0M
Capital spending-1.92M-2.38M-729.0K-3.07M-3.62M-1.16M-1.65M-134.0K-224.0M-326.0M
Free cash flow-405.1M-294.7M-188.9M-156.7M-123.2M-47.7M-13.5M-4.30M361.0M350.0M
Cash from investing-28.8M-204.1M83.3M87.2M-137.9M-45.7M-1.65M-134.0K-2.76B-2.15B
Cash from financing890.3M809.9M54.3M37.4M157.8M380.7M20.0M12.4M-1.30B2.74B
Dividends paid-22.0M-22.0M
Share buybacks20.0M7.42M
Change in cash458.3M313.4M-50.5M-29.1M-99.6M288.5M6.51M12.4M-3.47B1.27B

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
144 · Notice of proposed saleNov 13, 2026Other filingsSEC
144 · Notice of proposed saleNov 13, 2026Other filingsSEC
8-K · Current reportNov 5, 2026ResultsSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
4 · Change in ownershipOct 22, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 6, 2026Insider tradeSEC
8-K · Current reportSep 29, 2026Current reportSEC
144 · Notice of proposed saleSep 8, 2026Other filingsSEC
144 · Notice of proposed saleSep 8, 2026Other filingsSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
144 · Notice of proposed saleSep 4, 2026Other filingsSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
144 · Notice of proposed saleAug 14, 2026Other filingsSEC
144 · Notice of proposed saleAug 14, 2026Other filingsSEC
144 · Notice of proposed saleAug 14, 2026Other filingsSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2026Big-stake noticeSEC
8-K · Current reportJul 29, 2026ResultsSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
10-Q · Quarterly reportJul 29, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 28, 2026Big-stake noticeSEC
144 · Notice of proposed saleJul 27, 2026Other filingsSEC
424B5 · ProspectusJul 22, 2026Offer documentSEC
8-K · Current reportJul 22, 2026Material contractSEC
424B5 · ProspectusJul 21, 2026Offer documentSEC
8-K · Current reportJul 20, 2026Current reportSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
144 · Notice of proposed saleJun 24, 2026Other filingsSEC
144 · Notice of proposed saleJun 24, 2026Other filingsSEC
144 · Notice of proposed saleJun 24, 2026Other filingsSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 23, 2026Insider tradeSEC
8-K · Current reportJun 22, 2026Management or board changeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
144 · Notice of proposed saleJun 17, 2026Other filingsSEC
8-K · Current reportJun 17, 2026Material contractSEC
144 · Notice of proposed saleJun 16, 2026Other filingsSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
8-K · Current reportJun 8, 2026Meeting outcomeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
8-K · Current reportJun 3, 2026Current reportSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
144 · Notice of proposed saleMay 13, 2026Other filingsSEC
144 · Notice of proposed saleMay 13, 2026Other filingsSEC
8-K · Current reportMay 11, 2026ResultsSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
144 · Notice of proposed saleMay 6, 2026Other filingsSEC
144 · Notice of proposed saleMay 6, 2026Other filingsSEC
144 · Notice of proposed saleMay 6, 2026Other filingsSEC
144 · Notice of proposed saleMay 6, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeMay 6, 2026Big-stake noticeSEC
144 · Notice of proposed saleMay 5, 2026Other filingsSEC
144 · Notice of proposed saleMay 5, 2026Other filingsSEC
144 · Notice of proposed saleMay 5, 2026Other filingsSEC
144 · Notice of proposed saleMay 5, 2026Other filingsSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
4 · Change in ownershipApr 30, 2026Insider tradeSEC
4 · Change in ownershipApr 28, 2026Insider tradeSEC
144 · Notice of proposed saleApr 28, 2026Other filingsSEC
144 · Notice of proposed saleApr 28, 2026Other filingsSEC
144 · Notice of proposed saleApr 28, 2026Other filingsSEC
144 · Notice of proposed saleApr 28, 2026Other filingsSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
144 · Notice of proposed saleApr 27, 2026Other filingsSEC
144 · Notice of proposed saleApr 27, 2026Other filingsSEC
144 · Notice of proposed saleApr 27, 2026Other filingsSEC
144 · Notice of proposed saleApr 27, 2026Other filingsSEC
144 · Notice of proposed saleApr 24, 2026Other filingsSEC
144 · Notice of proposed saleApr 24, 2026Other filingsSEC
144 · Notice of proposed saleApr 24, 2026Other filingsSEC
144 · Notice of proposed saleApr 24, 2026Other filingsSEC
144 · Notice of proposed saleApr 23, 2026Other filingsSEC
144 · Notice of proposed saleApr 23, 2026Other filingsSEC
144 · Notice of proposed saleApr 23, 2026Other filingsSEC
144 · Notice of proposed saleApr 23, 2026Other filingsSEC
ARS · Annual report to shareholdersApr 23, 2026Annual reportSEC
4 · Change in ownershipApr 23, 2026Insider tradeSEC
DEFA14A · Additional proxy materialApr 23, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2026Meeting noticeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
144 · Notice of proposed saleApr 22, 2026Other filingsSEC
144 · Notice of proposed saleApr 22, 2026Other filingsSEC
144 · Notice of proposed saleApr 22, 2026Other filingsSEC
144 · Notice of proposed saleApr 22, 2026Other filingsSEC
144 · Notice of proposed saleApr 21, 2026Other filingsSEC
144 · Notice of proposed saleApr 21, 2026Other filingsSEC
144 · Notice of proposed saleApr 21, 2026Other filingsSEC
144 · Notice of proposed saleApr 21, 2026Other filingsSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
144 · Notice of proposed saleApr 20, 2026Other filingsSEC
144 · Notice of proposed saleApr 20, 2026Other filingsSEC
144 · Notice of proposed saleApr 20, 2026Other filingsSEC
144 · Notice of proposed saleApr 20, 2026Other filingsSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
PRE 14A · Preliminary proxy statementApr 9, 2026Meeting noticeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
144 · Notice of proposed saleApr 1, 2026Other filingsSEC
S-8 · Registration statement for employee plansMar 27, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
144 · Notice of proposed saleMar 11, 2026Other filingsSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
144 · Notice of proposed saleMar 9, 2026Other filingsSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 6, 2026Big-stake noticeSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
S-8 · Registration statement for employee plansMar 2, 2026Offer documentSEC
8-K · Current reportMar 2, 2026ResultsSEC
10-K · Annual reportMar 2, 2026Annual reportSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
8-K · Current reportJan 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJan 8, 2026Big-stake noticeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 23, 2025Insider tradeSEC
8-K · Current reportDec 23, 2025Management or board changeSEC
424B5 · ProspectusDec 10, 2025Offer documentSEC
8-K · Current reportDec 10, 2025Material contractSEC
424B5 · ProspectusDec 8, 2025Offer documentSEC
8-K · Current reportDec 8, 2025FinancingSEC
8-K · Current reportDec 8, 2025Current reportSEC
144 · Notice of proposed saleDec 5, 2025Other filingsSEC
144 · Notice of proposed saleDec 5, 2025Other filingsSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
8-K · Current reportNov 5, 2025ResultsSEC

This page holds 200 of 803 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Dyne Therapeutics, Inc.’s releases · as of Nov 17, 2026

Common shares
187,386,963
Fully diluted
187,667,163

Fully diluted

LineSharesAs of
Common shares187,386,963
Options and RSUs280,200Nov 17, 2026

Warrants and options

Lot
Stock options · expire about Nov 2036
RSUs · expiry not stated

Share count over time

CountShares
Nov 22, 2026187,386,963

Open Cap table

Shareholders

Institutions

HolderSharesValueChange vs Jun 30Filed
T. Rowe Price38MUS$612M+3.15MNov 16, 2026
BlackRock14.5MUS$233M+2.07MNov 13, 2026
Vanguard13.7MUS$221M+2.18MNov 13, 2026
Janus Henderson12MUS$194MFirst reportNov 16, 2026
Fidelity11.1MUS$180M−60,631Nov 10, 2026
Wellington10.6MUS$170M+10.5MNov 16, 2026
State Street8.16MUS$131M+700KNov 12, 2026
Orbis Allan Gray Ltd7.33MUS$118M+327KNov 16, 2026
Vestal Point Capital, LP6.2MUS$99.9M+2.83MNov 16, 2026
TCG Crossover Management, LLC4.62MUS$74.3MNo changeNov 16, 2026
Show 50 holders
HolderSharesValueChange vs Jun 30Filed
Geode Capital4.4MUS$70.8M+653KNov 6, 2026
Frazier Life Sciences Management, L.P.3.85MUS$62.1M+700KNov 16, 2026
Fcpm III Services B.V.3.59MUS$57.8M−261KNov 16, 2026
Atlas Venture Life Science Advisors, LLC3.44MUS$55.4M−3.36MNov 10, 2026
Mpm Bioimpact LLC3.21MUS$51.7M+1.29MNov 16, 2026
Logos Global Management LP3MUS$48.3M+450KNov 19, 2026
JPMorgan2.91MUS$47.4M−239KNov 12, 2026
Armistice Capital, LLC2.68MUS$43.1M−409KNov 16, 2026
Bank of America2.56MUS$41.2M+322KNov 16, 2026
Sofinnova Investments, Inc.2.51MUS$40.5M+853KNov 16, 2026
Siren, L.L.C.2.43MUS$39.1M+300KNov 12, 2026
Franklin Templeton2.39MUS$43.4M−51,186Nov 12, 2026
Polar Capital Holdings Plc2.27MUS$36.6M+985KNov 16, 2026
Venrock Adviser, LLC2.17MUS$35MNo changeNov 16, 2026
Goldman Sachs2.06MUS$33.2M−93,654Nov 16, 2026
Dimensional1.98MUS$32M+37,036Nov 4, 2026
Citadel1.95MUS$31.5M+811KNov 16, 2026
Samlyn Capital, LLC1.93MUS$31.1M+176KNov 16, 2026
Bain Capital Life Sciences Investors, LLC1.9MUS$30.6MNewNov 16, 2026
Palo Alto Investors LP1.88MUS$30.3M+234KNov 16, 2026
Schwab1.59MUS$25.6M+388KNov 16, 2026
Northern Trust1.47MUS$23.7M+195KNov 16, 2026
Fiera Capital Corp1.44MUS$23.1M+645KNov 6, 2026
Novo Holdings A/S1.38MUS$22.2M+416KNov 16, 2026
abrdn1.35MUS$21.8M−186KNov 10, 2026
Perceptive Advisors LLC1.27MUS$20.4M−1.42MNov 16, 2026
Balyasny Asset Management L.P.1.19MUS$19.1MNewNov 16, 2026
Morgan Stanley1.17MUS$18.9M+424KNov 13, 2026
UBS987KUS$15.9M+274KNov 16, 2026
Rock Springs Capital Management LP892KUS$14.4M−50,285Nov 16, 2026
Saturn V Capital Management LP837KUS$13.5M−220KNov 16, 2026
Baker Bros. Advisors LP813KUS$13.1MNo changeNov 16, 2026
BNY776KUS$12.5M+367KNov 5, 2026
Marshall Wace, LLP687KUS$11.1M−802KNov 13, 2026
Ghisallo Capital Management LLC650KUS$10.5MNewNov 19, 2026
TD612KUS$9.93M+64,268Nov 13, 2026
Raymond James Financial Inc544KUS$8.77M−32,162Nov 12, 2026
Vivo Capital, LLC514KUS$8.29M−1.04MNov 13, 2026
Tetragon Partners GP Ltd511KUS$8.24M+155KNov 16, 2026
ExodusPoint Capital Management, LP494KUS$7.96MNewNov 16, 2026

This page holds 50 of 259 holders. Open Shareholders

Funds

HolderSharesValueChangeAs of
T. Rowe Price Small-Cap Stock Fund, Inc.7MUS$156M−7,600Jun 30, 2026
T. Rowe Price Small-Cap Value Fund, Inc.4.6MUS$102M−22,452Jun 30, 2026
Vanguard Total Stock Market Index Fund4.47MUS$99.3M−174KJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF4.15MUS$92.2M+715KJun 30, 2026
T. Rowe Price Institutional Small-Cap Stock Fund3.81MUS$84.6MNo changeJun 30, 2026
iShares Russell 2000 ETF3.55MUS$78.9M+297KJun 30, 2026
T. Rowe Price Capital Appreciation Fund3.28MUS$72.8MNo changeJun 30, 2026
Fidelity Growth Company Fund2.86MUS$55.3M+1.11MMay 31, 2026
Vanguard Health Care Fund2.81MUS$70.7MNewJul 31, 2026
Janus Henderson Global Life Sciences Fund2.27MUS$50.5M−256KJun 30, 2026
Show 50 holders
HolderSharesValueChangeAs of
Select Biotechnology Portfolio1.88MUS$36.4M+515KMay 31, 2026
Vanguard Extended Market Index Fund1.69MUS$37.5M+86,842Jun 30, 2026
Fidelity Small Cap Index Fund1.66MUS$41.7M+339KJul 31, 2026
Vanguard Small-Cap Index Fund1.61MUS$35.8M−96,954Jun 30, 2026
T. Rowe Price New Horizons Fund, Inc.1.23MUS$27.4M+361KJun 30, 2026
Vanguard Small-Cap Value Index Fund1.02MUS$22.7M−66,096Jun 30, 2026
iShares Biotechnology ETF935KUS$20.8M+18,019Jun 30, 2026
JPMorgan Small Cap Growth Fund921KUS$20.5M−48,386Jun 30, 2026
iShares Russell 2000 Value ETF834KUS$18.5M+56,137Jun 30, 2026
Fidelity Growth Company K6 Fund793KUS$15.3M+289KMay 31, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund780KUS$17.3M+198KJun 30, 2026
Fidelity Series Growth Company Fund745KUS$14.4M+276KMay 31, 2026
Fidelity Extended Market Index Fund745KUS$14.4M−8,802May 31, 2026
JNL/T. Rowe Price Capital Appreciation Fund720KUS$16M+28,399Jun 30, 2026
Schwab U.S. Small-Cap ETF689KUS$13.3M−11,221May 31, 2026
Vanguard Russell 2000 Index Fund685KUS$13.2M+71,463May 31, 2026
Franklin Biotechnology Discovery Fund519KUS$13.1MNo changeJul 31, 2026
Fidelity Advisor Biotechnology Fund482KUS$12.1MNo changeJul 31, 2026
Franklin Small Cap Growth Fund479KUS$12.1M−26,593Jul 31, 2026
Dimensional U.S. Small Cap ETF479KUS$12.1M+88,408Jul 31, 2026
iShares Russell 2000 Growth ETF438KUS$9.73M+89,684Jun 30, 2026
Wasatch Ultra Growth Fund434KUS$9.63MNo changeJun 30, 2026
Artisan International Small-Mid Fund406KUS$9.01M+7,265Jun 30, 2026
U.S. Small Cap Portfolio386KUS$9.73M+191KJul 31, 2026
Schwab Small-Cap Index Fund369KUS$9.28M+75,939Jul 31, 2026
Vanguard Explorer Fund367KUS$9.24M+106KJul 31, 2026
T. Rowe Price Capital Appreciation Equity ETF358KUS$7.95M+10,167Jun 30, 2026
U.S. Micro Cap Portfolio353KUS$8.88M+118KJul 31, 2026
Vanguard Health Care Index Fund346KUS$6.69M+8,251May 31, 2026
Vy(R) T. Rowe Price Capital Appreciation Portfolio326KUS$7.25MNo changeJun 30, 2026
JPMorgan Small Cap Blend Fund293KUS$6.5M−20,211Jun 30, 2026
BlackRock Health Sciences Opportunities Portfolio279KUS$5.39MNo changeMay 29, 2026
Small Cap Value Portfolio277KUS$6.15M+57,796Jun 30, 2026
ClearBridge Small Cap Growth Fund276KUS$6.95MNo changeJul 31, 2026
Fidelity Total Market Index Fund272KUS$5.25M+4,846May 31, 2026
Master Small Cap Index Series249KUS$5.54M+43,143Jun 30, 2026
Penn Series Flexibly Managed Fund234KUS$5.2MNo changeJun 30, 2026
T. Rowe Price Spectrum Moderate Growth Allocation Fund228KUS$4.41M+27,107May 31, 2026
Fidelity Series Total Market Index Fund219KUS$4.23M+4,169May 31, 2026
Dimensional U.S. Core Equity 2 ETF218KUS$5.49M+94,634Jul 31, 2026

This page holds 50 of 234 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Posner Brian S
Director
Buy2,500USD 16.00US$40,000Oct 2, 2026
Cox John
Director, Officer: CEO & President
Sale5,658USD 18.88US$107KSep 8, 2026
Kerr Douglas
Officer: Chief Medical Officer
Sale1,290USD 18.88US$24,355Sep 8, 2026
Friedl-Naderer Johanna
Officer: Chief Commercial Officer
Sale185USD 18.88US$3,493Sep 8, 2026
Kerr Douglas
Officer: Chief Medical Officer
Sale3,745USD 24.35US$91,191Sep 4, 2026
Friedl-Naderer Johanna
Officer: Chief Commercial Officer
Sale900USD 24.35US$21,915Sep 4, 2026
Rhodes Jason P
Director
Sale1,359,674USD 25.00US$34MAug 14, 2026
Rhodes Jason P
Director
Sale478,377USD 25.00US$12MAug 14, 2026
Rhodes Jason P
Director
Sale322,465USD 25.00US$8.06MAug 14, 2026
Cox John
Director, Officer: CEO & President
Sale4,986USD 26.28US$131KAug 13, 2026
Show 50 trades
InsiderTradeSharesPriceValueDate
Rhodes Jason P
Director
Sale268,354USD 26.20US$7.03MAug 13, 2026
Rhodes Jason P
Director
Sale94,415USD 26.20US$2.47MAug 13, 2026
Rhodes Jason P
Director
Sale63,643USD 26.20US$1.67MAug 13, 2026
Lucera Erick
Officer: Chief Financial Officer
Sale1,797USD 26.28US$47,225Aug 13, 2026
Kerr Douglas
Officer: Chief Medical Officer
Sale1,556USD 26.28US$40,892Aug 13, 2026
Friedl-Naderer Johanna
Officer: Chief Commercial Officer
Sale226USD 26.28US$5,939Aug 13, 2026
Kersten Dirk
Director
Sale256,072USD 25.50US$6.53MJul 27, 2026
Kersten Dirk
Director
Sale5,388USD 26.04US$140KJul 27, 2026
Rhodes Jason P
Director
Sale124,379USD 23.17US$2.88MJul 7, 2026
Rhodes Jason P
Director
Sale29,587USD 23.62US$699KJul 7, 2026
Rhodes Jason P
Director
Sale62,543USD 23.17US$1.45MJul 7, 2026
Rhodes Jason P
Director
Sale14,844USD 23.62US$351KJul 7, 2026
Rhodes Jason P
Director
Sale49,193USD 23.17US$1.14MJul 7, 2026
Rhodes Jason P
Director
Sale11,665USD 23.62US$276KJul 7, 2026
Rhodes Jason P
Director
Sale5,000USD 23.61US$118KJul 7, 2026
Rhodes Jason P
Director
Sale253,039USD 22.79US$5.77MJul 6, 2026
Rhodes Jason P
Director
Sale127,182USD 22.79US$2.9MJul 6, 2026
Rhodes Jason P
Director
Sale100,019USD 22.79US$2.28MJul 6, 2026
Rhodes Jason P
Director
Sale102,969USD 21.14US$2.18MJun 29, 2026
Rhodes Jason P
Director
Sale51,756USD 21.14US$1.09MJun 29, 2026
Rhodes Jason P
Director
Sale40,702USD 21.14US$860KJun 29, 2026
Rhodes Jason P
Director
Sale162,954USD 21.28US$3.47MJun 26, 2026
Rhodes Jason P
Director
Sale81,903USD 21.28US$1.74MJun 26, 2026
Rhodes Jason P
Director
Sale64,411USD 21.28US$1.37MJun 26, 2026
Lucera Erick
Officer: Chief Financial Officer
Sale2,362USD 20.37US$48,114Jun 25, 2026
Rhodes Jason P
Director
Sale12,699USD 21.10US$268KJun 25, 2026
Rhodes Jason P
Director
Sale6,382USD 21.10US$135KJun 25, 2026
Rhodes Jason P
Director
Sale5,019USD 21.10US$106KJun 25, 2026
Rhodes Jason P
Director
Sale50,530USD 21.02US$1.06MJun 24, 2026
Rhodes Jason P
Director
Sale25,397USD 21.02US$534KJun 24, 2026
Rhodes Jason P
Director
Sale19,973USD 21.02US$420KJun 24, 2026
Rhodes Jason P
Director
Sale77,855USD 21.13US$1.65MJun 23, 2026
Rhodes Jason P
Director
Sale39,131USD 21.13US$827KJun 23, 2026
Rhodes Jason P
Director
Sale30,774USD 21.13US$650KJun 23, 2026
Kersten Dirk
Director
Sale71,629USD 21.04US$1.51MJun 23, 2026
Kersten Dirk
Director
Sale1,657USD 21.47US$35,576Jun 23, 2026
Kersten Dirk
Director
Sale190,676USD 20.57US$3.92MJun 22, 2026
Kersten Dirk
Director
Sale46,901USD 20.07US$941KJun 18, 2026
Kersten Dirk
Director
Sale37,454USD 20.14US$754KJun 17, 2026
Cox John
Director, Officer: CEO & President
Sale2,683USD 18.33US$49,179Jun 16, 2026

This page holds 50 of 117 trades. Open Shareholders

Big stakes

HolderStakeSharesDate
T. Rowe Price Investment Management, Inc.18.70%30.8MMar 31, 2026
Janus Henderson Group PLC7.30%12MJun 30, 2026
BlackRock, Inc.7.00%11.5MJun 30, 2026
FMR LLC6.80%11.2MJun 30, 2026
Wellington Management Group LLP5.70%10.6MSep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David Lubner
Other companies: Braveheart Bio, Inc. (Director · Since at least Aug 5, 2026); Crescent Biopharma, Inc. (Director · Since at least Jun 13, 2025); CARGO Therapeutics, Inc. (Director · Since at least Nov 9, 2023); Arcellx Inc (Director · Since at least Feb 3, 2022); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Vor Biopharma Inc. (Director · Feb 4, 2021 – May 22, 2025 · Past); POINT Biopharma Global Inc (Director · Jul 7, 2020 – Dec 26, 2023 · Past); Nightstar Therapeutics PLC (Director · Jan 1, 2019 – Jun 7, 2019 · Past); Ra Pharmaceuticals Inc (Executive VP and CFO · Oct 25, 2016 – Apr 2, 2020 · Past); Tetraphase Pharmaceuticals Inc (SVP and CFO · Mar 19, 2013 – Aug 14, 2015 · Past)
Board Member · Since at least Jul 31, 2020
Barry Greene
Other companies: Sage Therapeutics Inc (President and CEO, Director · Since at least Sep 30, 2020); Karyopharm Therapeutics Inc. (Director · Since at least Nov 5, 2013); BCLS Acquisition Corp (Director · Oct 22, 2020 – Oct 22, 2020 · Past); Regulus Therapeutics Inc (Director · Oct 4, 2012 – Nov 5, 2012 · Past); Acorda Therapeutics Inc (Director · Jan 9, 2007 – Jun 2, 2021 · Past); Alnylam Pharmaceuticals, Inc. (President · Oct 31, 2006 – Sep 9, 2020 · Past)
Board Member · Since at least Jun 22, 2026
Brian S. Posner
Other companies: BG Medicine Inc (Director · Since at least Feb 13, 2012); Arch Capital Group Ltd. (Director · Since at least Nov 4, 2010); Bioverativ Inc (Director · Jan 10, 2017 – Mar 8, 2018 · Past); Anadys Pharmaceuticals Inc (Director · Aug 22, 2011 – Aug 22, 2011 · Past); Biogen Inc. (Director · Jul 23, 2008 – Dec 31, 2022 · Past); LMP Capital and Income Fund Inc (Officer of the Adviser · Oct 11, 2006 – Oct 11, 2006 · Past)
Board Member · Since at least Oct 1, 2025
Erick J. Lucera
Other companies: SAB Biotherapeutics, Inc. (Director · Since at least Apr 3, 2023); Beyond Air, Inc. (Audit Chair · Since at least Aug 10, 2017); Editas Medicine, Inc. (EVP, CHIEF FINANCIAL OFFICER · May 17, 2023 – Mar 8, 2025 · Past); Bone Biologics Corp (Director · Oct 15, 2021 – Sep 18, 2023 · Past); AVEO Pharmaceuticals Inc (Chief Financial Officer · Jan 6, 2020 – Jan 19, 2023 · Past); Valeritas Holdings Inc (See Remarks · Mar 22, 2017 – Mar 7, 2019 · Past)
Chief Financial Officer · Since at least Mar 31, 2025
Edward Hurwitz
Other companies: MacroGenics, Inc. (Director · Since at least Oct 9, 2013); Turmeric Acquisition Corp (Chief Financial Officer · Oct 15, 2020 – Oct 15, 2020 · Past); Tvardi Therapeutics, Inc. (Director · Jan 30, 2014 – Feb 5, 2014 · Past); Sunesis Pharmaceuticals Inc (Director · Apr 3, 2009 – Jun 28, 2013 · Past)
Director · Since at least Jul 31, 2020
Jason Rhodes
Other companies: Generation Bio Co (Director · Since at least Jun 11, 2020); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Replimune Group, Inc. (Director · Jul 19, 2018 – Apr 1, 2022 · Past); Epizyme Inc (President, CFO and Treasurer · May 30, 2013 – Sep 22, 2014 · Past)
Chairman · Since at least Sep 16, 2020
John Cox
Other companies: Sigilon Therapeutics Inc (Director · Dec 3, 2020 – Aug 11, 2023 · Past); Bioverativ Inc (Chief Executive Officer, Director · Dec 22, 2016 – Mar 8, 2018 · Past); Repligen Corporation (Director · Nov 15, 2013 – Mar 24, 2020 · Past); Biogen Inc. (EVP Pharmaceutical Oper & Tech · Nov 1, 2011 – Apr 1, 2016 · Past)
President and Chief Executive Officer · Since at least Mar 25, 2024
Lawrence Klein
Other companies: Jade Biosciences, Inc. (Chief Executive Officer, Oruka Therapeutics · Since at least Apr 28, 2025); Oruka Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Aug 29, 2024); Jasper Therapeutics, Inc. (Director · Sep 24, 2021 – Jun 7, 2023 · Past); CRISPR Therapeutics AG (CBO & COO · Jan 2, 2019 – Aug 16, 2022 · Past)
Director · Jul 31, 2020 – Jul 5, 2022 · Past
Catherine Stehman-Breen
Other companies: Tenaya Therapeutics, Inc. (Board Member · Since at least Jul 29, 2021); Generation Bio Co (Director · Since at least Jun 11, 2020); Sarepta Therapeutics, Inc. (SVP, Chief Medical Officer · Apr 3, 2017 – Apr 3, 2017 · Past)
Board Member · Since at least Jul 31, 2020
Joshua Brumm
Other companies: Crescent Biopharma, Inc. (Chief Executive Officer · Since at least Jun 13, 2025); Kaleido Biosciences, Inc. (See Remarks · Feb 27, 2019 – Mar 4, 2019 · Past); Aravive Inc (COO and CFO · Nov 12, 2015 – Oct 19, 2017 · Past)
CEO & President, Director · Sep 16, 2020 – Mar 8, 2024 · Past
All 33 people
PersonSeat
Lucia Celona
Other companies: Apellis Pharmaceuticals, Inc. (See Remarks · Aug 5, 2019 – Feb 10, 2020 · Past); Bioverativ Inc (EVP, HR & Corp Commun. Officer · Dec 22, 2016 – Mar 8, 2018 · Past)
Chief Human Resources Officer · Since at least Nov 5, 2026
Richard William Scalzo
Other companies: Crescent Biopharma, Inc. (Chief Financial Officer · Since at least Jun 13, 2025); Kaleido Biosciences, Inc. (Principal Accounting Officer · Oct 11, 2019 – Oct 11, 2019 · Past)
SVP, Head of Finance & Admin. · Sep 16, 2020 – Mar 11, 2025 · Past
Douglas Kerr
Other companies: Generation Bio Co (CHIEF MEDICAL OFFICER · Jun 11, 2020 – Jan 29, 2024 · Past)
Head of R&D and CMO · Since at least Sep 3, 2024
Johanna Friedl-Naderer
Other companies: Vir Biotechnology, Inc. (EVP & Chief Operating Officer · Mar 2, 2022 – Mar 3, 2023 · Past)
Chief Commercial Officer · Since at least Sep 3, 2024
Jonathan McNeill
Other companies: Crescent Biopharma, Inc. (President and Chief Operating Officer · Since at least Jun 13, 2025)
Chief Business Officer · Sep 16, 2020 – Aug 19, 2024 · Past
Susanna Gatti High
Other companies: Bluebird bio Inc (Chief Operating Officer · Dec 1, 2016 – Dec 6, 2018 · Past)
Chief Operating Officer · Sep 16, 2020 – Sep 18, 2024 · Past
Vikram Karnani
Other companies: Collegium Pharmaceutical, Inc. (PRESIDENT & CHIEF EXECUTIVE OFFICER · Since at least Nov 7, 2024)
Board Member · Since at least Dec 22, 2025
Alessandro MartuscelliChief Legal Officer · Since at least Nov 5, 2026
Axel WiestSenior Vice President, Head of Portfolio Strategy & Operations · Since at least Nov 5, 2026
Carlo IncertiBoard Member · Since at least Mar 2, 2022
Debra FeldmanChief Regulatory Affairs Officer · Since at least Nov 5, 2026
Dirk KerstenBoard Member · Since at least Jul 31, 2020
Doug KerrHead of Research & Development and Chief Medical Officer · Since at least Sep 29, 2026
Ed HurwitzBoard Member · Since at least Nov 4, 2026
James P. BilottaChief Digital Information Officer · Since at least Nov 5, 2026
José JuvesChief Corporate & Patient Affairs Officer · Since at least Nov 5, 2026
Monica FayChief Medical Affairs Officer · Since at least Nov 5, 2026
Oxana BeskrovnayaChief Innovation Officer · Since at least Sep 16, 2020
Raj ManchandaChief Technical Officer · Since at least Nov 5, 2026
Ranjan BatraChief Scientific Officer · Since at least Sep 3, 2026
Romesh SubramanianChief Scientific Officer · Sep 16, 2020 – Sep 16, 2020 · Past
Vikram RanadeChief Business Officer · Since at least May 8, 2025
Wildon FarwellChief Medical Officer · Mar 1, 2021 – Aug 19, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Dyne Therapeutics, Inc.